Table 2.
Treatment description
| None (n = 55) | Grade 1–2 (n = 50) | Grade 3–4 (n = 46) | p value (lonckheere-Terpstra test) | |
|---|---|---|---|---|
| Chemo-naïve | 33 (60%) | 21 (42%) | 27 (58.7%) | 78 |
| Prior chemotherapy | ||||
| Platinums | 4 (7%) | 2 (4%) | 3 (6.5%) | 0.83 |
| Anthracyclines | 8 (14.6%) | 7 (14.0%) | 4 (8.7%) | 0.40 |
| Taxanes | 7 (12.7%) | 5 (10.0%) | 3 (6.5%) | 0.30 |
| 5-Fluorouracil | 6 (10.9%) | 7 (14.0%) | 4 (8.7%) | 0.77 |
| Gemcitabine | 12 (21.8%) | 14 (28%) | 13 (28.3%) | 0.44 |
| Other | 10 (18.2%) | 13 (26%) | 5 (10.9%) | 0.42 |
| Gemcitabine regimen | 0.36 | |||
| Gem. alone | 40 (72.7%) | 38 (76%) | 30 (65%) | |
| Gem. + other chemotherapy | 7 (12.7%) | 8 (16%) | 10 (21.7%) | |
| Gem. + non -chemotherapy | 7 (12.7%) | 4 (8%) | 6 (13%) | |
| Gem. + other | 1 (1.8%) | 0 | 0 | |
| Cycles received | 3 (1,11) | 4 (1,14) | 4 (1,15) | <0.000l |
| Dose of gemcitabine | 0.0075 | |||
| 1,000 mg/m2 | 45 (81.8%) | 45 (90%) | 45 (97.8%) | |
| 750mg/m2 | 3 (5.5%) | 3 (6%) | 1 (2.2%) | |
| Other | 7 (12.7%) | 2 (4%) | 0 (0%) | |
| Schedule | 0.40 | |||
| Days 1 and 8: 3-week cycle | 31 (56.4%) | 25 (50%) | 30 (65.2%) | |
| Days 1,8 and 15:4-week cycle | 17 (30.9%) | 21 (42%) | 12 (26.1%) | |
| Every other week | 6 (10.9%) | 3 (6%) | 1 (2.2%) | |
| Other | 1 (1.8%) | 1 (2%) | 3 (6.5%) | |
| GCSF treatment | 0 (0%) | 0 (0%) | 3 (6.5%) | 0.03 |
| Gem. delayed/held | 0 (0%) | 2 (4%) | 28 (61%) | <0.0001 |
| Gem. dose adjusted | 0 (0%) | 3 (6%) | 29 (63.0%) | <0.000l |
| Gem. stopped early | 44 (80%) | 35 (70%) | 24 (52.2%) | 0.003 |